Cell therapy’s chief executive, Keith Thompson (left), met with Vince Cable MP
Cell Therapy Catapult has made a deal with iPS Academia Japan that is thought to be of strategic importance to the British cell therapy community, according to a press release on 16 January.
Under the patent licence agreement, the London-based centre can sub-licence, manufacture and commercialise lines of induced pluripotent stem cells (iPSCs) for use in early-stage research and clinical trials.
Pioneered in Kyoto in 2006, iPSCs are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state and hold promise as useful tools for drug development, the modelling of diseases and regenerative medicine.
